On the stock market since 1990, it operates in the world of health and science. It has 30 employees. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
The biggest line carries real weight, but it doesn’t decide everything on its own.
No real growth (1% a year). Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Revenue Growth: Sales are growing slowly.
An investor who bought at the very peak is down 73% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
The company sells $3.3M a year; the problem isn’t sales — it’s costs running above that number.
A loss of $100K against $3.3M in annual sales.
The stock sits at $0.04. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
On our five-subject report card, ADMT sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: ADMT is a small company that closed last year at a loss. The road back to profit runs through spending discipline.